Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
23 September 2022Website:
http://www.biohavenpharma.comNext earnings report:
31 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 21:19:39 GMTDividend
Analysts recommendations
Institutional Ownership
BHVN Latest News
Biohaven Ltd. (BHVN) is currently in an oversold condition, suggesting that the intense selling pressure may have come to an end.
The intense selling pressure for Biohaven Ltd. (BHVN) may have subsided as it is currently in oversold territory from a technical standpoint.
Biotech stocks are filled with exciting innovators who may contribute to increased profits in the future. It is difficult to predict which medications and treatments in a company's pipeline will become successful and profitable.
With tech giants and other industry leaders announcing their latest quarterly results, it is not surprising that significant insider purchases are likely to be rare.
Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
What type of business is Biohaven Pharmaceutical Holding?
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
What sector is Biohaven Pharmaceutical Holding in?
Biohaven Pharmaceutical Holding is in the Healthcare sector
What industry is Biohaven Pharmaceutical Holding in?
Biohaven Pharmaceutical Holding is in the Biotechnology industry
What country is Biohaven Pharmaceutical Holding from?
Biohaven Pharmaceutical Holding is headquartered in United States
When did Biohaven Pharmaceutical Holding go public?
Biohaven Pharmaceutical Holding initial public offering (IPO) was on 23 September 2022
What is Biohaven Pharmaceutical Holding website?
https://www.biohavenpharma.com
Is Biohaven Pharmaceutical Holding in the S&P 500?
No, Biohaven Pharmaceutical Holding is not included in the S&P 500 index
Is Biohaven Pharmaceutical Holding in the NASDAQ 100?
No, Biohaven Pharmaceutical Holding is not included in the NASDAQ 100 index
Is Biohaven Pharmaceutical Holding in the Dow Jones?
No, Biohaven Pharmaceutical Holding is not included in the Dow Jones index
When does Biohaven Pharmaceutical Holding report earnings?
The next expected earnings date for Biohaven Pharmaceutical Holding is 31 July 2024